These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 9693220)
41. [Nitric oxide, vasodilatation and cirrhosis: a double (dys)equilibrium]. Sogni P; Moreau R; Lebrec D Gastroenterol Clin Biol; 1999 Jan; 23(1):101-4. PubMed ID: 10219610 [No Abstract] [Full Text] [Related]
42. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability. Lee KC; Yang YY; Huang YT; Lee FY; Hou MC; Lin HC; Lee SD Clin Sci (Lond); 2010 Apr; 119(1):45-55. PubMed ID: 20132096 [TBL] [Abstract][Full Text] [Related]
43. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Wiest R; Groszmann RJ Hepatology; 2002 Feb; 35(2):478-91. PubMed ID: 11826425 [No Abstract] [Full Text] [Related]
45. ADMA correlates with portal pressure in patients with compensated cirrhosis. Vizzutti F; Romanelli RG; Arena U; Rega L; Brogi M; Calabresi C; Masini E; Tarquini R; Zipoli M; Boddi V; Marra F; Laffi G; Pinzani M Eur J Clin Invest; 2007 Jun; 37(6):509-15. PubMed ID: 17537159 [TBL] [Abstract][Full Text] [Related]
46. Pathophysiology and a Rational Basis of Therapy. Gracia-Sancho J; Maeso-Díaz R; Bosch J Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267 [TBL] [Abstract][Full Text] [Related]
47. Splanchnic hyposensitivity to glypressin in a haemorrhage/transfused rat model of portal hypertension: role of nitric oxide and bradykinin. Chu CJ; Wu SL; Lee FY; Wang SS; Chang FY; Lin HC; Chan CC; Lee SD Clin Sci (Lond); 2000 Dec; 99(6):475-82. PubMed ID: 11099389 [TBL] [Abstract][Full Text] [Related]
48. Molecular and structural basis of portal hypertension. Moreau R; Lebrec D Clin Liver Dis; 2006 Aug; 10(3):445-57, vii. PubMed ID: 17162222 [TBL] [Abstract][Full Text] [Related]
49. Favorable clinical outcome using a covered stent following transjugular intrahepatic portosystemic shunt in patients with portal hypertension. Wu X; Ding W; Cao J; Han J; Huang Q; Li N; Li J J Hepatobiliary Pancreat Sci; 2010 Sep; 17(5):701-8. PubMed ID: 20703849 [TBL] [Abstract][Full Text] [Related]
50. [Rapid increase in portal pressure in idiopathic portal hypertension--a case report]. Nishida O; Harada H; Tsuji M; Hosotani Y; Hishita T; Hada S; Saka Y; Horii J; Ohno T; Seko S Nihon Shokakibyo Gakkai Zasshi; 1994 Oct; 91(10):1997-2003. PubMed ID: 7967138 [No Abstract] [Full Text] [Related]
51. Chronological changes in renal vascular reactivity in portal hypertensive rats. Chuang CL; Huang HC; Chang CC; Lee FY; Wu JC; Lee SD Eur J Clin Invest; 2013 Mar; 43(3):267-76. PubMed ID: 23293840 [TBL] [Abstract][Full Text] [Related]
52. Acute-on-chronic liver failure: the liver and portal haemodynamics. Mookerjee RP Curr Opin Crit Care; 2011 Apr; 17(2):170-6. PubMed ID: 21346568 [TBL] [Abstract][Full Text] [Related]
53. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Niederberger M; Ginés P; Martin PY; Tsai P; Morris K; McMurtry I; Schrier RW Hepatology; 1996 Oct; 24(4):947-51. PubMed ID: 8855203 [TBL] [Abstract][Full Text] [Related]
54. Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Biecker E; Trebicka J; Kang A; Hennenberg M; Sauerbruch T; Heller J Liver Int; 2008 Mar; 28(3):331-8. PubMed ID: 18290775 [TBL] [Abstract][Full Text] [Related]
55. Role of nitric oxide synthase and cyclooxygenase in hyperdynamic splanchnic circulation of portal hypertension. Xu J; Cao H; Liu H; Wu ZY Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):503-8. PubMed ID: 18842497 [TBL] [Abstract][Full Text] [Related]
56. Effect of laparoscopic splenectomy on portal haemodynamics in patients with liver cirrhosis and portal hypertension. Kawanaka H; Akahoshi T; Kinjo N; Iguchi T; Ninomiya M; Yamashita YI; Ikegami T; Yoshizumi T; Shirabe K; Maehara Y Br J Surg; 2014 Nov; 101(12):1585-93. PubMed ID: 25200126 [TBL] [Abstract][Full Text] [Related]
57. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. Hernández-Guerra M; García-Pagán JC; Bosch J J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S131-7. PubMed ID: 15758648 [TBL] [Abstract][Full Text] [Related]